Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Wednesday morning. The brokerage issued a sell rating on the stock.

SYRS has been the topic of several other research reports. HC Wainwright restated a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Trading Down 10.5 %

Syros Pharmaceuticals stock opened at $0.21 on Wednesday. The company has a 50 day moving average price of $0.66 and a 200 day moving average price of $2.40. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. Syros Pharmaceuticals has a 52 week low of $0.18 and a 52 week high of $7.98. The firm has a market capitalization of $5.63 million, a price-to-earnings ratio of -0.07 and a beta of 1.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same quarter in the previous year, the company posted ($1.35) earnings per share. Research analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Buying and Selling

In other news, Director Nancy A. Simonian sold 134,713 shares of Syros Pharmaceuticals stock in a transaction on Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares in the company, valued at $11,088.90. The trade was a 76.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 12.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Syros Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Exome Asset Management LLC increased its position in shares of Syros Pharmaceuticals by 87.6% during the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after acquiring an additional 139,400 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in Syros Pharmaceuticals during the 3rd quarter worth approximately $34,000. 91.47% of the stock is owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.